Biomaterials in healthcare span almost all medical fields, ranging from recognised materials to high-innovative smart and multi-functional biomaterials. One of the main challenges is to provide accessible and well-structured data of biomaterials for all relevant practitioners and user groups. BIOMATDB aims to create an advanced database for biomaterials providing detailed information on its properties. Flexible data analysis and visualisation tools support the search and selection process based on analyses of the results of biological testing of biomaterials from the scientific literature to incorporate data on as many of the material properties as possible. BIOMATDB also provides a web-optimised information marketplace and digital advisors to support companies, especially SMEs, in offering their products and properly presenting themselves at global scale. Initiated by biomaterial use cases, the web application will match the suppliers and demanders through intelligent matching tools and step-by-step decision support. BIOMATDB focuses on the creation of a label of biocompatibility to define the suitability of a biomaterial for use in a medical device or advanced therapy and to assist companies, especially SMEs, in choosing and facilitating market access for their products providing them a better guidance. All created technical systems and data processing methods are tested within existing open innovation testbeds and validation groups. Intuitive training manuals and compact online video tutorials support the use of the database, marketplace and label. Appropriate business models are derived for securing the long-term sustainability of the created solutions. The project has a significant impact on the findability and searchability of existing biomaterials at the pan-European level. It is an enabler for better uptake of biomaterials in future health applications and medical therapies.

SECURE project aims to make a major contribution to the sustainability of medical isotope production and its safe application in Europe. It is focusing on promising developments in the design of irradiation targets, production routes for existing and new isotopes in nuclear therapy and diagnostics. Isotopes critical in the success of nuclear medicine are selected and research activities are identified to address some of the major challenges in securing its future availability, with the objectives: 1. to remove critical barriers along the production of its selected alpha and beta emitting isotopes that restrict a sustainable production, 2. to develop a framework of guidance and recommendations that enables exploring the full clinical potential of alpha and beta particle therapy and its safe application 3. to provide important lessons learned that act as a demonstration case for addressing issues in upscaling and sustained isotope production. At present, Ra-223 is the only radiopharmaceutical which has been granted marketing authorization to treat adults with prostate cancer. This has paved the way for a wider use of other alpha emitters such as Ac-225 or Bi-213. The expected demand of nuclear medicine for novel alpha emitters and beta- emitters requires re-evaluation of their production methods and inventories of target materials and parent radionuclides. The ambition of SECURE consortium is to identify and efficiently use the current resources for new radionuclides, in particular for alpha emitters and the relevant beta emitting theranostic radionuclides. The development of alternative technologies for production of such therapeutic radionuclides for improved patient treatment requires multidisciplinary scientific and technological knowledge including physics, chemistry, material science, machining of target materials, chemistry, biology and radiobiology, radiopharmacy and nuclear medicine. All this chain of expertise is present in SECURE consortium.

The general purpose of PRECISEU is connecting innovation ecosystems across Europe to efficiently advance towards a truly personalised healthcare, transferring practices and solutions from region to region and scaling up deep-tech healthcare innovations based on advanced therapies medicinal products and health data across Europe. The PRECISEU consortium is composed of Regional Authorities and innovation players from 9 NUTS 1 and 2 regions, supported by clusters, universities, research centres and infrastructures, NGOs and networks, and engaging regional and European innovators, scientists and entrepreneurs across the EU health innovation space. Also involved as partner in the consortium, one Ukrainian Region, Rivne, represented by the Rivne Medical Cluster, has a relevant role as Ukraine is open for cooperation, innovation and joint projects for reconstruction. The European continent faces a set of challenges in terms of the swift and effective implementation of medical care, which were brought sharply into focus during the COVID-19 pandemic. Healthcare remains a concurrent gap between innovation leaders and emerging and moderate innovators (classification according to the Regional Innovation Scoreboard, RIS), which impacts all spheres (economics, social and living standards), and which requires significant expertise and knowledge as well as expansive collaboration between innovation networks and all stakeholders and communities across Europe. PRECISEU is aware that taking next steps in the development and organisation of PM is a key issue for Europe, and that more coordination efforts between key European stakeholders is necessary to foster its implementation. By focusing on health data and advanced therapies as key drivers of personalized medicine models, PRECISEU will not only provide regional ecosystems with European connectivity but will most importantly address the significant and urgent needs of the regions.